Primary Pulmonary Hypertension is behind multiple hospitalizations and pulmonary transplants. Even though its treatment has been advanced, many patients will not respond well.
The PADN-CFDA randomized 128 patients, 63 received pulmonary denervation (PADN) and 65 went to the control group.
Primary end point was 6-minute walk distance test at 6 months.
The populations were similar, mean age was 44 and 90% were women.
Primary end point resulted in favor of PADN, in addition to reducing NT pro BNP and pulmonary vascular resistance.
The 6-month Eco-Doppler showed improved right ventricular function and improved tricuspid regurgitation, and the right catheterization procedure showed reduced pulmonary artery hypertension and increased volume per minute.
Read also: TCT 2022 | RADIANCE II Pivotal Trial.
The authors have concluded that PADN is safe, improves 6-minute walk distance and also brings about improved eco-Doppler and pulmonary hypertension, reduced pulmonary vascular resistance and decreased NT pro BNP.
Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.
Original Title: Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomised Trial
Presenter: ShaoLiang Ch.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
